financetom
Business
financetom
/
Business
/
Guess? Fiscal Q1 Adjusted Loss Widens, Revenue Rises; Q2 Outlook Set -- Shares Fall After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Guess? Fiscal Q1 Adjusted Loss Widens, Revenue Rises; Q2 Outlook Set -- Shares Fall After Hours
May 30, 2024 3:03 PM

05:34 PM EDT, 05/30/2024 (MT Newswires) -- Guess? (GES) reported fiscal Q1 adjusted loss Thursday of $0.27 per diluted share, widening from a loss of $0.07 a year earlier.

Four analysts polled by Capital IQ expected a loss of $0.40.

Revenue for the quarter that ended May 4 was $591.9 million, up from $569.8 million a year earlier.

Analysts surveyed by Capital IQ expected $574.6 million.

The company expects a Q2 adjusted EPS of $0.38 to $0.47 on revenue growth of between 9% and 11%. Four analysts polled by Capital IQ expect a net income of $0.65 on sales of $761.7 million.

The company expects fiscal 2025 adjusted EPS of $2.62 to $3.00 on revenue growth of 10.7% to 12.7%. Four analysts surveyed by Capital IQ expected earnings of $2.81 on revenue of $3.11 billion.

Guess? said its board approved a quarterly dividend of $0.30 per share, payable on June 28 to shareholders of record on June 12.

Shares of the company fell nearly 3% in after-hours trading.

Price: 22.73, Change: -0.66, Percent Change: -2.84

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Celcuity Submits New Drug Application for Gedatolisib to Treat Breast Cancer
Celcuity Submits New Drug Application for Gedatolisib to Treat Breast Cancer
Nov 17, 2025
04:25 PM EST, 11/17/2025 (MT Newswires) -- Celcuity ( CELC ) said late Monday it submitted a new drug application to the US Food and Drug Administration for gedatolisib to treat advanced breast cancer. The NDA was submitted under the regulator's Real-Time Oncology Review program, designed to facilitate shorter review periods, the company said. The NDA submission was founded on...
XP Q3 Earnings, Net Revenue Rise
XP Q3 Earnings, Net Revenue Rise
Nov 17, 2025
04:26 PM EST, 11/17/2025 (MT Newswires) -- XP (XP) reported Q3 earnings late Monday of 2.47 Brazilian reais ($0.46) per diluted share, up from 2.18 reais a year earlier. Analysts polled by FactSet expected 2.43 reais. Net revenue rose to 4.66 billion reais from 4.32 billion reais a year earlier. Analysts surveyed by FactSet expected 4.66 billion reais. XP shares...
Brazil's XP posts 12% rise in Q3 net profit, announces share buyback
Brazil's XP posts 12% rise in Q3 net profit, announces share buyback
Nov 17, 2025
SAO PAULO, Nov 17 (Reuters) - Brazilian financial services platform XP Inc ( XP ) reported on Monday a 1.3 billion real ($243.88 million) third-quarter net profit, up 12% from a year earlier. * XP launched a new share buyback program totaling 1 billion reais, and announced 500 million reais in dividends. * Gross revenue rose 9% to 4.9 billion...
Vita Coco Company Insider Sold Shares Worth $437,226, According to a Recent SEC Filing
Vita Coco Company Insider Sold Shares Worth $437,226, According to a Recent SEC Filing
Nov 17, 2025
04:25 PM EST, 11/17/2025 (MT Newswires) -- John Zupo, Director, on November 14, 2025, sold 10,000 shares in Vita Coco Company ( COCO ) for $437,226. Following the Form 4 filing with the SEC, Zupo has control over a total of 12,162 common shares of the company, with 12,162 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1482981/000188672625000006/xslF345X05/edgardoc.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved